Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 04, 2025, titled "Zydus receives EIR for the injectable facility located at Jarod".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zydus Lifesciences has received an Establishment Inspection Report (EIR) from the US FDA for its injectable manufacturing facility at Jarod, Gujarat. An EIR is issued by the US FDA once it closes an inspection of a manufacturing site, indicating that the audit has been formally concluded. This is an important regulatory milestone as the injectable facility contributes to Zydus's US generics and injectables business. A clean EIR with no further action generally signals compliance and clears the path for continued or new product approvals from this site.
Positive for shareholders — closure of the USFDA inspection without observations (or with acceptable ones) supports uninterrupted manufacturing and future product approvals from the Jarod facility, strengthening Zydus's US injectable franchise.